XRAY
DENTSPLY SIRONA Inc.
Medical - Instruments & Supplies
Market Cap$2.20B
5Y Perf.-76.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
XRAY vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
HOLX
Hologic, Inc.
Medical - Instruments & Supplies
Market Cap$16.97B
5Y Perf.+42.6%
XRAY vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | XRAY | HOLX |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $2.20B | $16.97B |
| Revenue (TTM) | $3.68B | $4.13B |
| Net Income (TTM) | $-628M | $544M |
| Gross Margin | 48.9% | 52.8% |
| Operating Margin | 4.1% | 17.5% |
| Forward P/E | 7.7x | 17.2x |
| Total Debt | $2.47B | $2.63B |
| Cash & Equiv. | $326M | $1.96B |
XRAY vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
XRAY
HOLX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 23.6 | -76.4% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XRAY vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HOLX leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DENTSPLY SIRONA Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
XRAY
DENTSPLY SIRONA Inc.
The Growth Play
XRAY is the clearest fit if your priority is growth exposure.
- Rev growth -3.0%, EPS growth 33.0%, 3Y rev CAGR -2.1%
- Lower P/E (7.7x vs 17.2x)
- 5.9% yield; 23-year raise streak; the other pay no meaningful dividend
Best for: growth exposure
HOLX
Hologic, Inc.
The Income Pick
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.41
- 124.3% 10Y total return vs XRAY's -74.5%
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HOLX | 1.7% revenue growth vs XRAY's -3.0% |
| Value | XRAY | Lower P/E (7.7x vs 17.2x) |
| Quality / Margins | HOLX | 13.2% margin vs XRAY's -17.1% |
| Stability / Safety | HOLX | Beta 0.41 vs XRAY's 1.78, lower leverage |
| Dividends | XRAY | 5.9% yield; 23-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | HOLX | +37.1% vs XRAY's -16.4% |
| Efficiency (ROA) | HOLX | 6.1% ROA vs XRAY's -11.2%, ROIC 9.4% vs 5.1% |
XRAY vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2025
XRAY vs HOLX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHOLXLAGGINGXRAY
XRAYDENTSPLY SIRONA Inc.
1leads
HOLXHologic, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs XRAYMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HOLX6/6
Valuation MetricsMultiples, price ratios, and targets
XRAY5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HOLX8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
HOLX6/6
Risk & VolatilityBeta, volatility, and downside exposure
HOLX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HOLX leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX and XRAY operate at a comparable scale, with $4.1B and $3.7B in trailing revenue. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to XRAY's -17.1%.
| Metric | XRAYDENTSPLY SIRONA I… | HOLXHologic, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $3.7B | $4.1B |
| EBITDAEarnings before interest/tax | $424M | $974M |
| Net IncomeAfter-tax profit | -$628M | $544M |
| Free Cash FlowCash after capex | $104M | $1000M |
| Gross MarginGross profit ÷ Revenue | +48.9% | +52.8% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +17.5% |
| Net MarginNet income ÷ Revenue | -17.1% | +13.2% |
| FCF MarginFCF ÷ Revenue | +2.8% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +0.1% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -150.0% | -9.2% |
HOLX leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
XRAY leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, XRAY's 7.2x EV/EBITDA is more attractive than HOLX's 17.4x.
| Metric | XRAYDENTSPLY SIRONA I… | HOLXHologic, Inc. |
|---|---|---|
| Market CapShares × price | $2.2B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -3.65x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.68x | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 7.18x | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 0.60x | 4.14x |
| Price / BookPrice ÷ Book value/share | 1.63x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 21.11x | 18.44x |
XRAY leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
HOLX leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-41 for XRAY. HOLX carries lower financial leverage with a 0.52x debt-to-equity ratio, signaling a more conservative balance sheet compared to XRAY's 1.84x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs XRAY's 6/9, reflecting strong financial health.
| Metric | XRAYDENTSPLY SIRONA I… | HOLXHologic, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -41.2% | +11.0% |
| ROA (TTM)Return on assets | -11.2% | +6.1% |
| ROICReturn on invested capital | +5.1% | +9.4% |
| ROCEReturn on capital employed | +6.1% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 1.84x | 0.52x |
| Net DebtTotal debt minus cash | $2.1B | $667M |
| Cash & Equiv.Liquid assets | $326M | $2.0B |
| Total DebtShort + long-term debt | $2.5B | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | -5.12x | 8.00x |
HOLX leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
HOLX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HOLX five years ago would be worth $11,582 today (with dividends reinvested), compared to $1,991 for XRAY. Over the past 12 months, HOLX leads with a +37.1% total return vs XRAY's -16.4%. The 3-year compound annual growth rate (CAGR) favors HOLX at -2.9% vs XRAY's -32.6% — a key indicator of consistent wealth creation.
| Metric | XRAYDENTSPLY SIRONA I… | HOLXHologic, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -2.8% | +1.9% |
| 1-Year ReturnPast 12 months | -16.4% | +37.1% |
| 3-Year ReturnCumulative with dividends | -69.4% | -8.5% |
| 5-Year ReturnCumulative with dividends | -80.1% | +15.8% |
| 10-Year ReturnCumulative with dividends | -74.5% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -32.6% | -2.9% |
HOLX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than XRAY's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs XRAY's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XRAYDENTSPLY SIRONA I… | HOLXHologic, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 0.41x |
| 52-Week HighHighest price in past year | $17.18 | $76.04 |
| 52-Week LowLowest price in past year | $9.85 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 39.2 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 10.0M |
HOLX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates XRAY as "Hold" and HOLX as "Hold". Consensus price targets imply 22.3% upside for XRAY (target: $13) vs 3.9% for HOLX (target: $79). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | XRAYDENTSPLY SIRONA I… | HOLXHologic, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $13.40 | $79.00 |
| # AnalystsCovering analysts | 31 | 42 |
| Dividend YieldAnnual dividend ÷ price | +5.9% | — |
| Dividend StreakConsecutive years of raises | 23 | — |
| Dividend / ShareAnnual DPS | $0.64 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
HOLX leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 1 (Valuation Metrics).
Best OverallHologic, Inc. (HOLX)Leads 4 of 6 categories
Loading custom metrics...
XRAY vs HOLX: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is XRAY or HOLX a better buy right now?
For growth investors, Hologic, Inc.
(HOLX) is the stronger pick with 1. 7% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate DENTSPLY SIRONA Inc. (XRAY) a "Hold" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XRAY or HOLX?
On forward P/E, DENTSPLY SIRONA Inc.
is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — XRAY or HOLX?
Over the past 5 years, Hologic, Inc.
(HOLX) delivered a total return of +15. 8%, compared to -80. 1% for DENTSPLY SIRONA Inc. (XRAY). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus XRAY's -74. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XRAY or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus DENTSPLY SIRONA Inc. 's 1. 78β — meaning XRAY is approximately 334% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — XRAY or HOLX?
By revenue growth (latest reported year), Hologic, Inc.
(HOLX) is pulling ahead at 1. 7% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: DENTSPLY SIRONA Inc. grew EPS 33. 0% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, XRAY leads at -2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — XRAY or HOLX?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus -16. 3% for DENTSPLY SIRONA Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus 6. 8% for XRAY. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is XRAY or HOLX more undervalued right now?
On forward earnings alone, DENTSPLY SIRONA Inc.
(XRAY) trades at 7. 7x forward P/E versus 17. 2x for Hologic, Inc. — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRAY: 22. 3% to $13. 40.
08Which pays a better dividend — XRAY or HOLX?
In this comparison, XRAY (5.
9% yield) pays a dividend. HOLX does not pay a meaningful dividend and should not be held primarily for income.
09Is XRAY or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). DENTSPLY SIRONA Inc. (XRAY) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, XRAY: -74. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between XRAY and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: XRAY is a small-cap income-oriented stock; HOLX is a mid-cap quality compounder stock. XRAY pays a dividend while HOLX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(XRAY: 0.1% · HOLX: 2.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.